Gene Expression Profiling Tests are:
a form of personalized medicine to learn more about your cancer and to customize your treatment.

These tests are typically for breast cancer patients with early stage estrogen receptor-positive (ER+) and lymph node negative cancer or less than 2 lymph nodes. The test is done on breast cancer cells typically after surgery to look at different gene patterns. This process is sometimes called gene expression profiling.

The results can help predict if certain early stage breast cancers are likely to recur.

Genomic test results, when considered with other features of the breast cancer, can help you and your doctor make a more informed decision about the effectiveness of chemotherapy or other treatments to reduce the risk of recurrence.

This is not the same as genetic testing for cancer risk.

Purpose of tests
These tests help predict the risk of recurrence of a current cancer. Knowing the risk of recurrence may be important information to decide if a patient may benefit from more aggressive treatment.

Who is appropriate to consider for test
Patients should discuss if these tests are appropriate for them with their cancer care medical providers.

- Not indicated for chemotherapy based on other factors
- Smaller tumors, usually smaller than 5 cm
- Early stage, usually Stage I or II
- Usually only for HER2 negative breast cancer

Example tests
Oncotype DX® - It is used to predict the risk of recurrence of early-stage, hormone-receptor-positive breast cancer.

Mammaprint® - test is used to predict the risk of recurrence within 10 years after diagnosis of stage I or stage II breast cancer that is hormone-receptor-positive or hormone-receptor-negative.

Prosigna Breast Cancer Prognostic Gene Signature Assay® - is used to predict the risk of distant recurrence for postmenopausal women within 10 years of diagnosis of early-stage cancer after 5 years of hormonal therapy.

EndoPredict® - is used to predict the risk of distant recurrence of early-stage, hormone-receptor-positive, HER2-negative breast cancer that is either node-negative or has up to three positive lymph nodes.

Breast Cancer Index Test® is used to predict the risk of node-negative, hormone-receptor-positive breast cancer coming back 5 to 10 years after diagnosis.

Discuss with your medical provider if this type of test is appropriate for your situation.

If you are looking for genetic testing for cancer risk, see: [https://www.cancer.net/navigating-cancer-care/cancer-basics/genetics](https://www.cancer.net/navigating-cancer-care/cancer-basics/genetics)

Resources for Additional Information:
- American Cancer Society, Breast Cancer Gene Expression Tests
- Breastcancer.org, MammaPrint Test
- Breastcancer.org, Women Diagnosed With Breast Cancer Consider Genomic Tests Hugely Important, but Many Don’t Understand Results
- NIH, The TAILORxBreast Cancer Trial, originally published by the National Cancer Institute

Recursos en Español:
- American Cancer Society, Pruebas para la expresión genética del cáncer de seno

The information contained in this document is designed to help a cancer patient but may not reflect the latest guidance or current standard of practice. Equal Hope is not licensed to provide any medical or clinical advice and cannot provide any assurance as to the accuracy or relevance of any information in this document and disclaims all warranties of any kind or responsibility whatsoever regarding its content, use, or application. Under no circumstances should any information be understood to be medical advice.